Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

Monocentric study composed by 2 steps : 1. First step is a phase I with the aim of establish the recommended dose of mirdametinib administration (2 or 4 mg twice a day for 7 or 14 days per cycle for the 4 first of carboplatin/pemetrexed/pembrolizumab treatment) 2. Second step is a non comparative randomized (2:1) phase II trial testing the recommended dose of mirdametinib administration. The aim is the efficacy and safety of short course of mirdametinib treatment for the 4 first cycles of the carboplatin/pemetrexed/pembrolizumab treatment.

Trial Details

NCT ID
NCT05937906
Phase
PHASE1 / PHASE2
Sponsor
Centre Georges Francois Leclerc
Status
RECRUITING
Cancer Type
Squamous Cell Lung Cancer
Interventions
  • Phase I - Mirdametinib - Level 1
  • Phase II - Mirdametinib
  • Phase I - Mirdametinib - Level 2
  • Phase I - Mirdametinib - Level 3
  • Phase I - Mirdametinib - Level 4
Locations (sample)
  • Dijon, Burgundy, France|47.31344,5.01391

Key Eligibility Criteria

  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF…
  • Patients must be diagnosed with a metastatic or locally advanced non squamous non-small cell lung cancer
  • Absence of previous treatment for or locally advanced or metastatic non-small cell lung cancer. Previous adjuvant therapy is allowed if \> 12 month…
  • Age \>18 years at time of study entry

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Lung Cancer Trials on Trialify →